Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR1 | P21462 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CXCR6 | O00574 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3216309 | 0.94 | FPR1 (0.41) | FPR1USP30TAS1R3TAS1R1SMN1; SMN2 | |
| SCHEMBL13490382 | 0.83 | ALDH1A1 (0.52) | USP30SMN1; SMN2POLBKDM4EGID4 | |
| Hydrochloric Acid SCHEMBL3199563 | 0.82 | ALDH1A1 (0.51) | USP30SMN1; SMN2POLBKDM4EGID4 | |
| SCHEMBL13490664 | 0.82 | RAB9A (0.59) | FPR1SMN1; SMN2KDM4ENPC1RAB9A | |
| SCHEMBL13490630 | 0.81 | SMYD3 (0.56) | USP30SMN1; SMN2GID4NPC1RAB9A | |
| SCHEMBL13490654 | 0.81 | SMN1; SMN2 (0.48) | USP30SMN1; SMN2POLBKDM4EGID4 | |
| Hydrochloric Acid SCHEMBL3224400 | 0.81 | SMYD3 (0.55) | USP30SMN1; SMN2GID4NPC1RAB9A | |
| SCHEMBL13490686 | 0.80 | CXCR6 (0.46) | USP30SMN1; SMN2GID4RAB9ACXCR6 | |
| SCHEMBL3207604 | 0.80 | SMN1; SMN2 (0.45) | USP30SMN1; SMN2POLBKDM4EGID4 | |
| SCHEMBL14192746 | 0.80 | SMN1; SMN2 (0.45) | USP30SMN1; SMN2POLBKDM4EGID4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | ACIN1, HAT1, CCNE1 | FPR1 3951/4885USP30 4315/4885TAS1R3 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.